Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire May 26, 2022

Mersana Therapeutics Announces FDA Grant of Orphan Drug Designation to XMT-2056 for the Treatment of Gastric Cancer

GlobeNewswire May 19, 2022

Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

GlobeNewswire May 9, 2022

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 6, 2022

Mersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022

GlobeNewswire May 2, 2022

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 6, 2022

Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

GlobeNewswire April 5, 2022

Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer

GlobeNewswire March 15, 2022

Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

GlobeNewswire March 2, 2022

Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire February 28, 2022

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2021 Financial Results and Business Updates

GlobeNewswire February 22, 2022

Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates

GlobeNewswire February 3, 2022

Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones

GlobeNewswire January 7, 2022

Mersana Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2022

Mersana Therapeutics Named to 2021 List of Top Places to Work in Massachusetts by The Boston Globe

GlobeNewswire December 2, 2021

Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 23, 2021

Mersana Therapeutics to Present at the Upcoming Stifel 2021 Virtual Healthcare Conference

GlobeNewswire November 10, 2021

Mersana Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 9, 2021

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2021 Financial Results and Business Updates

GlobeNewswire November 2, 2021